



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 1/02	A1	(11) International Publication Number: WO 99/20104 (43) International Publication Date: 29 April 1999 (29.04.99)
<p>(21) International Application Number: PCT/GB98/03160</p> <p>(22) International Filing Date: 22 October 1998 (22.10.98)</p> <p>(30) Priority Data: 9722156.8 22 October 1997 (22.10.97) GB</p> <p>(71)(72) Applicants and Inventors: ACTON, Elizabeth [GB/GB]; New Hall, Huntingdon Road, Cambridge CB3 0DF (GB). MORRIS, George, John [GB/GB]; Thatched Cottage, Caxton Road, Boum, Cambridge CB5 7SX (GB).</p> <p>(74) Agents: WAIN, Christopher, Paul et al.; A.A. Thornton & Co., Northumberland House, 303-306 High Holborn, London WC1V 7LE (GB).</p>		<p>(81) Designated States: AU, CA, GB, IL, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: METHOD AND APPARATUS FOR CRYOPRESERVATION</p> <p>(57) Abstract</p> <p>A method of cryopreserving biological material, which method comprises providing a sample of the biological material, where a liquid phase of the sample includes at least one solute; lowering the temperature of the sample to a nucleating point at which ice nucleation can occur in the sample; effecting ice nucleation in the sample; and lowering the sample temperature from the nucleating point to the solidification point thereof, characterised in that the temperature lowering from the nucleating point to the solidification point is non linear, whereby the rate of change of solute concentration in the liquid phase decreases for more than 80 % of the time taken to lower the temperature from the nucleating point to the solidification point.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Licchtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

METHOD AND APPARATUS FOR CRYOPRESERVATION

The present invention relates to a method and apparatus for cryopreserving biological material including, for example, cell suspensions, such as embryos, gametes, (spermatozoa, oocytes) cell lines, bone marrow, blood stem cells and the like; solutions of proteins and/or other biologically active substances; and perfused tissues and organs, either engineered or obtained from a natural source.

Cryopreservation is a process where samples such as biological materials are stored at low temperatures. Cryopreservation of biological material substantially as described above is generally effected by freezing in appropriate retaining means, such as flexible bags, glass or plastic ampoules, or plastic tubes (usually referred to as "straws" in the field of cryopreservation) of the type suitable for long term storage at the low temperatures employed.

Although cryopreservation has been widely employed for a range of biological materials, there are certain materials for which it is not suitable. For example, with certain materials, cellular injury can occur on thawing. Furthermore, cryopreservation is not applicable for cell types where recovery on thawing may either be low or very variable, or even non-existent. For example, recovery on thawing of sub-fertile human spermatozoa, human testicular spermatozoa, pig spermatozoa and the like is generally low or variable, and in other cases such as mammalian oocytes, fish eggs, fish embryos, tissues, organs or the like, survival is non-existent.

Furthermore, on thawing cryopreserved material, cell survival can be dependent on the conditions and techniques employed, such as

appropriate nucleation techniques, addition of suitable cryoprotective additives and also the control of the cooling rate. Nucleation, for example, is known to be a problem when not externally controlled in cryopreservation techniques, and occurs at a wide range of temperatures below the melting point of individual materials. While some materials nucleate at or just below the melting point, others may not nucleate until the temperature has reached up to 20°C below the melting point, for example, with cell suspensions contained in straws or ampoules the range of temperature is particularly wide, both because the volume of the suspensions, and hence the number of available heteronuclei, is small and also because the containers are generally sealed before freezing, thus removing the possibility of seeding by airborne ice nuclei in the freezer. Nucleation at temperatures significantly away from melting points of materials requiring cryopreservation has resulted in transient temperature changes and cell death even when cooling rates have apparently been optimised for survival (Whittingham D. G., In The Freezing Of Mammalian Embryos, Ciba Foundation Symposium 52, pp 98-102, 1977).

In order to nucleate biological materials in a reproducible manner, it is common practice firstly to cool the materials to a temperature below the melting point thereof, then after a short period of thermal equilibration, to nucleate ice in the supercooled material. Nucleation can be achieved by any of the following techniques – application of cold forceps to the outside of the material, by cold wires, by devices employing “reverse Peltier effects” or by the application of physical disturbances. An alternative method of ensuring nucleation near to the melting point is to incorporate an ice nucleating agent into the biological suspension before temperature reduction. Examples of ice nucleating agents include the so called ice nucleating bacteria for example *Pseudomonas syringae*, the active proteins from ice nucleating bacteria and organic compounds such as cholesterol. Following nucleation and initial crystal growth, cooling of the materials is then resumed.

However, monitoring the success of the nucleation procedure and

also subsequent crystal growth has proved to be a problem. In conventional controlled rate freezing equipment, it is not possible to monitor subsequent crystal growth following nucleation without removing the straws from the equipment for visual inspection. A high risk of melting is associated with such removal. Furthermore, at present no method is available in such equipment to monitor, in a non-invasive manner, the success of the nucleation procedure.

Problems have also been encountered as a result of the techniques employed to lower the temperature following nucleation. It is common practice that during cryopreservation, biological materials are cooled with, as far as possible, a linear reduction in temperature with time. Cryopreservation equipment is generally designed to control the material environment in a linear manner, and depending on the heat transfer characteristics of the equipment, the materials cool in a more or less linear manner. Whilst this approach is convenient for simple design of equipment and has produced acceptable results with a range of cell types, it has proved unsatisfactory with a number of cellular materials.

WO96/02801 discusses the importance of employing a linear cooling rate over the entire cooling phase employed in cryopreservation, and is concerned with the provision of a cooling assembly capable of obtaining a substantially linear and reproducible rate of cooling samples.

WO96/24018 is concerned with the cryopreservation of mammalian tissue, or living cultured equivalents made by in vitro technology. The temperature control employs linear temperature lowering, but different rates of linear temperature lowering are respectively employed in different stages of the cryopreservation process. More particularly, the temperature is initially lowered at a rate of $-10.0^{\circ}\text{C}/\text{minute}$ to the solid-liquid phase equilibrium temperature range for an employed cryoprotectant, and following propagation of ice seed crystals throughout the cryoprotectant cooling is resumed at a rate of between -0.02 to about $-0.3^{\circ}\text{C}/\text{minute}$.

US 4799358 describes freezing of biological material, and also

employs linear temperature lowering but with different rates of linear temperature lowering being respectively employed in different stages of the freezing process. For example, the temperature is typically initially lowered at a rate of $-0.5^{\circ}\text{C}/\text{minute}$ between $+20^{\circ}\text{C}$ and -7°C and then $-0.3^{\circ}\text{C}/\text{minute}$ between -7°C and -35°C .

The use of non-linear cooling rates has also been discussed in the prior art. WO91/01635 is concerned with a cooling process and apparatus where the material being frozen is subjected to a greater rate of heat extraction when the latent heat is being given up during nucleation, than when the material is cooled further. WO91/01635 indicates that the heat extraction rates may be non-linear, but does not provide clear guidance as to the parameters of non-linear heat extraction employed.

We have now devised a method and apparatus for cryopreserving biological material, which method and apparatus reduce or alleviate the problems associated with the prior art. In particular, we have devised a method and apparatus to reduce or overcome the problems associated with cellular freezing injury.

According to the present invention, there is provided a method of cryopreserving biological material, which method comprises: providing a sample of the biological material, where a liquid phase of the sample includes at least one solute; lowering the temperature of the sample to a nucleating point at which ice nucleation can occur in the sample; effecting ice nucleation in the sample; and lowering the temperature of the sample from the nucleating point to the solidification point thereof, characterised in that the temperature lowering from the nucleating point to the solidification point is non-linear, whereby the rate of change of solute concentration in the liquid phase decreases for more than 80% of the time taken to lower the temperature from the nucleating point to the solidification point.

Preferably, in the method of the invention the liquid phase is aqueous and, preferably, the biological sample is suspended or dissolved therein.

The term "solidification point" as used herein denotes the temperature at which substantially all the liquid phase of the sample solidifies, or vitrifies. This temperature can be determined from a phase diagram or may be measured by differential scanning calorimetry. For simple solutions, the solidification point is the eutectic temperature.

Preferably, the method of the present invention comprises determining the melting point of the sample. Suitably, the melting point can be determined based on the osmolality of the liquid phase, and a method according to the present invention aptly further comprises determining the osmolality of the liquid phase. Osmolality can be determined by any convenient technique known in the art, such as solidification point osmometry, or may be calculated from the composition of the liquid phase. The equilibrium phase diagram during solidification or freezing can then be constructed by an appropriate method, including experimental measurement, by reference to standard text (for example the CRH Handbook of Chemistry and Physics) or scientific publication (for example Rasmussen & McKenzie, *Nature* 220, 1315-1317, 1968, Shepard *et al.*, *Cryobiology* 13, 9-23, 1976, Lane, *Ind. Engr. Chem.* 17, 924, 1925). For solutions with unpublished or incomplete phase diagrams, and for complex mixed solutions, the phase diagram may be approximated by any well defined system, for example glycerol and water (Lane, *Ind. Engr. Chem.* 17, 924, 1925).

The method according to the present invention preferably includes determining the nucleating point of the sample. Preferably, the nucleating point should be substantially close to the melting point. In a particularly preferred embodiment, the nucleating point should not be less than about 4°C below the melting point. Even more preferably, the nucleating point should not be less than about 2°C below the melting point. Ice nucleation can be achieved by employing any known prior art techniques substantially as herein before described.

In a first embodiment of the present invention, the method can further comprise a step of thermal re-equilibration following ice nucleation. In a

second embodiment of the present invention, for example where large sample volumes (such as cell suspensions, or perfused tissues or organs) are being cryopreserved in flexible bags, substantially no re-equilibration is carried out.

Substantially as herein before described, the temperature lowering from the nucleating point to the solidification point is non-linear, so that the rate of change of solute concentration in the liquid phase decreases for more than 80% of the time taken to lower the temperature from the nucleating point to the solidification point. It will be appreciated, however, that any particular such non-linear thermal profile will be substantially dependent on the biological material being cryopreserved, the concentration thereof, solute concentration or concentrations and also the presence of any other additives in the sample.

It is further particularly preferred that temperature lowering from the nucleating point to the solidification point is non-linear so that the rate of change of solute concentration in the liquid phase decreases for more than 90% of the time taken to lower the temperature from the nucleating point to the solidification point. Advantageously, the change in solute concentration during the time taken to lower the temperature from the nucleating point to the solidification point is closely approximated by

$$A = 26.9 + 30.6 \tan^{-1} \{(t + t_0 - 0.385)/1.17\}$$

where t is the time at which the temperature is begun to be lowered from the nucleating point, and t_0 is determined from the concentration A_0 according to the equation

$$t_0 = 0.385 + 1.17 \tan \{0.0327(A_0 - 26.9)\}.$$

Typically, the sample employed in a method according to the present invention contains one or more cryoprotectants. A suitable cryoprotectant can include a solution of glycerol, fructose and sodium citrate.

The method according to the present invention preferably further involves determining the time to be taken for the non-linear temperature lowering from the nucleating point to the solidification point. The time elapsed from the nucleation point to the solidification point can be dependent on a number of factors, such as the biological material being cryopreserved, and suitably also the cryoprotectant employed, and can be determined in a number of ways.

For example, the elapsed time can suitably substantially correspond to the time that would be taken from the nucleating point to the solidification point where the optimal linear rate of cooling was employed for a selected biological material. The optimal linear rate of cooling for mammalian spermatozoa is -10°C and -0.3°C for mammalian embryos. This optimum linear rate of cooling may be estimated from a knowledge of the basic biophysical parameters that determine osmotic behaviour during solidification.

Particularly for cell suspensions, perfused tissues or organs, however, the elapsed time during the non-linear cooling employed in the present invention can be determined by modelling the osmotic behaviour during solidification. Accordingly, the elapsed time may be determined by selecting the shortest time that achieves sufficient water loss so as to substantially avoid any intracellular ice formation in the cells of the biological material, during any of the temperature lowering steps employed in the present invention.

Biological material employed in a method according to the present invention suitably comprises cell suspensions, such as embryos, gametes (spermatozoa, oocytes), cell lines, bone marrow, blood stem cells or the like; solutions of proteins and/or other biologically active substances; and perfused tissues and organs, either engineered or obtained from a natural source.

There is further provided by the present invention biological material substantially as herein before described cryopreserved by a method substantially as herein before described.

There is still further provided by the present invention apparatus

for cryopreserving a biological material, which apparatus comprises means for receiving one or more samples of the biological material, where a liquid phase of the sample or samples includes at least one solute; means for lowering the temperature of the sample or samples to a nucleating point thereof at which ice nucleation can occur in the sample or samples; means for effecting ice nucleation in the sample or samples; and means for lowering the temperature of the sample or samples from the nucleating point to a solidification point thereof, characterised in that the temperature lowering means effect non-linear temperature lowering from the nucleating point to the solidification point, whereby the rate of change of solute concentration in the liquid phase decreases for more than 80% of the time taken to lower the temperature from the nucleating point to the solidification point.

Suitably the receiving means of apparatus according to the present invention are dimensioned so as to be suitable for receiving sample retaining means generally employed in cryopreservation, such as plastic tubes (commonly known in the field of cryopreserving as "straws") for the biological sample or samples. Appropriately, the receiving means can comprise a grooved (typically machined) holder for the retaining means such as straws, and can generally comprise a suitable thermally conductive material. Generally, the grooved holder is substantially horizontally arranged for receiving the straws. Alternatively, where the retaining means comprise plastic ampoules or glass vials, the holder can comprise substantially vertically arranged apertures for receiving these retaining means. Where plastic ampoules are employed as the retaining means, it is generally preferable to employ transparent lids for the ampoules to facilitate nucleation detection substantially as herein after described.

The apparatus appropriately further comprises means for illuminating one or more biological samples arranged therein. The illuminating means may simply comprise a light source remotely arrangeable relative to the receiving means to illuminate straws or the like. Alternatively, the illuminating means may comprise transparent plug means for axially illuminating samples

being cryopreserved according to the present invention. In the latter case, the presence of ice can be indicated by sideways scattering from a resulting axial light beam.

It may be desirable for the receiving means to be adapted (for example by surface colour and/or finish modification) to enhance detection of optical contrast occurring following nucleation. Suitably, an indicator may be included in a sample being cryopreserved according to the present invention so that changes in selected physical properties of the sample can be detected following ice formation. For example, a pH indicator capable of providing a colorimetric indication of pH change may be employed.

It is further preferred that apparatus according to the present invention further comprises means for viewing a sample or samples arranged therein. For example, the receiving means may suitably be arrangeable within a chamber of which at least one wall portion comprises a transparent material so as to allow viewing of a sample or samples arranged in the chamber. The wall portion may comprise an insulating material, such as Perspex, and may further be provided with an insulating cover that may be removed to allow inspection of a sample or samples being cryopreserved according to the present invention. In this way, if nucleation has been unsuccessful this can be detected and substantially rectified. For example, nucleation may be repeated for a sample or samples that have been detected not to have previously undergone nucleation, and this will not be detrimental for samples in the apparatus according to the present invention that have previously undergone successful nucleation.

This aspect of the present invention is particularly advantageous, as successful detection of ice nucleation can be an important parameter in achieving successful cryopreservation.

The temperature lowering means employed in apparatus according to the present invention may comprise a feedback loop incorporating means of temperature measurement, a controller and a thin film heater.

The present invention will now be further illustrated by the

following figures and example, which do not limit the scope of the invention in any way.

Figure 1 is a side view of a holder (1) for receiving horizontally arranged straws (2) containing suspensions to be cryopreserved, where the suspensions are illuminated by a remote light source (3).

Figure 2 is a plan view of holder (1) shown in Figure 1.

Figure 3 is a side view of a holder (1) for receiving horizontally arranged straws (2) containing suspensions to be cryopreserved, where the suspensions are illuminated through light guides (8).

Figure 4 is a plan view of holder (1) shown in Figure 3.

Figure 5 is a side view of a passive cooler for use in method and apparatus according to the present invention.

Figures 1 and 2 show suspension holder (1) in which suspensions are illuminated by a light source (3). Light source (3) is positioned so as to enable ice within straws (2) to be visualised through a viewing window (4). Heat is continually extracted from holder (1) through an insulating plate (5) to a cold heat sink (6). The temperature of holder (1) is measured by any suitable technique, such as a thermocouple (not shown) and a thin film heater (7) is then used to control the temperature of holder (1) as required. Temperature control during solidification is achieved using any suitable controller that may be programmed to achieve non-linear rates of temperature change.

Figures 3 and 4 show holder (1) in which straws (2) are illuminated axially through light guides (8) at the end of straws (2). Light source (3) provides light to guide 8.

Figure 5 shows a passive cooler suitable for use in method and apparatus according to the present invention. The temperature of holder (1) up to ice nucleation of the suspensions is controlled by upper thin-film heater (7) backing off the cooling to heat sink (6). Two insulated plates (5) and (9) are used, with a second thin-film heater (10) therebetween. Heater (10) is used to maintain the temperature at the bottom of upper insulated plate (5) at a

predetermined temperature (T_1). After nucleation, the upper heater (7) is switched off and holder (1) then cools passively to temperature T_1 . After a predetermined time second heater (10) is switched off and holder (1) cools to the temperature of cold heat sink (6).

Example 1

Cryopreservation of human spermatozoa

Normal human sperm was diluted into a cryoprotectant solution containing glycerol, fructose and sodium citrate prior to freezing. The osmolality of the cell suspension was measured to be 1430 mOsm/Kg by freezing point osmometry, equivalent to an aqueous glycerol solution of 13.5w/v. The temperature-time curve to achieve a change in solute concentration of the unfrozen fraction that was decreasing for >90% of the elapsed time was then determined and is shown in Figure 6 together with the calculated time-concentration curve shown in Figure 7. The elapsed time from -5°C (the nucleation temperature) to -45°C (the eutectic temperature for glycerol/water was 4 minutes.

Straws (0.25ml IMV, L'Aigle France) were filled with the cell suspension and sealed with PVA powder. The straws were placed in apparatus of the type shown in Figure 1 and cooled from 20°C to -5°C at a rate of 2°C/min. At -5°C the straws were nucleated within the equipment by touching the straw at the free surface of the liquid column with a nucleating tool that had been cooled by immersion into liquid nitrogen. Confirmation that ice had formed in all straws was achieved by direct observation of illuminated straws on the cooling plate. The temperature of the straws was then reduced to -45°C following the temperature time curve shown in Figure 6. Straws were then cooled to -100°C at a rate of 10°C/min and then transferred to liquid nitrogen for storing. When required straws were then thawed at room temperature and the motility assessed.

With all sperm samples examined sperm frozen by a method according to the present invention had a significantly higher recovery than sperm

frozen by a passive vapour phase cooling protocol or by linear cooling at a rate of $-10^{\circ}\text{C}/\text{min}$ within a conventional controlled rate freezer. For example, with sperm from one ejaculate, vapour phase cooling yielded 60% motile sperm on thawing whilst linear cooling within a controlled rate freezer yielded 66%, samples frozen by a method according to the present invention had a recovery on thawing of 88%.

CLAIMS:

1. A method of cryopreserving biological material, which method comprises: providing a sample of the biological material, where a liquid phase of the sample includes at least one solute; lowering the temperature of the sample to a nucleating point at which ice nucleation can occur in the sample; effecting ice nucleation in the sample; and lowering the temperature of the sample from the nucleating point to its solidification point, characterised in that the temperature lowering from the nucleating point to the solidification point is non-linear, whereby the rate of change of solute concentration in the liquid phase decreases for more than 80% of the time taken to lower the temperature from the nucleating point to the solidification point.
2. A method according to claim 1, which further comprises determining the melting point of the sample.
3. A method according to claim 1 or 2, which further comprises determining the osmolality of the liquid phase.
4. A method according to any of claims 1 to 3, which further comprises determining the nucleating point of the sample.
5. A method according to any of claims 1 to 4, wherein the nucleating point should not be less than about 4°C below the melting point.
6. A method according to claim 5, wherein the nucleating point should not be less than about 2°C below the melting point.
7. A method according to any of claims 1 to 6, wherein the method further comprises the step of thermal re-equilibration following nucleation.

8. A method according to any of claims 1 to 7, wherein lowering the temperature from the nucleating point to the solidification point is non-linear so that the rate of change of solute concentration in the liquid phase decreases for more than 90% of the time taken to lower the temperature from the nucleating point to the solidification point.

9. A method according to any of claims 1 to 8, wherein the change in solute concentration during the time taken to lower the temperature from the nucleating point to the solidification point is closely approximated by

$$A = 26.9 + 30.6 \tan^{-1} \{(t + t_0 - 0.385)/1.17\}$$

where t is the time at which the temperature is begun to be lowered from the nucleating point, and t_0 is determined from the concentration A_0 according to the equation

$$t_0 = 0.385 + 1.17 \tan \{0.0327(A_0 - 26.9)\}.$$

10. A method according to any of claims 1 to 9, wherein the sample contains a cryoprotectant.

11. A method according to any of claims 1 to 10, wherein the sample contains an ice nucleating agent.

12. Apparatus for cryopreserving a biological material, which apparatus comprises means for receiving one or more samples of the biological material, where a liquid phase of the sample or samples includes at least one solute; means for lowering the temperature of the sample or samples to a nucleating point thereof at which ice nucleation can occur in the sample or samples; means for effecting ice nucleation in the sample or samples; and

means for lowering the temperature of the sample or samples from the nucleating point to a solidification point thereof, characterised in that the temperature lowering means effect non-linear temperature lowering from the nucleating point to the solidification point, whereby the rate of change of solute concentration in the liquid phase decreases for more than 80% of the time taken to lower the temperature from the nucleating point to the solidification point.

13. Apparatus according to claim 12, which further comprises means for illuminating and viewing the one or more samples therein.

14. Apparatus according to claim 13, wherein the illuminating means may comprise a light source arrangeable to illuminate horizontally arranged straws.

15. Apparatus according to claim 13, wherein the illuminating means comprise transparent plug means for axially illuminating a sample or samples.

16. Apparatus according to any of claims 12 to 15, wherein the sample receiving means are adapted to enhance detection of optical contrast occurring following ice nucleation.

17. Apparatus according to any of claims 12 to 16, wherein the temperature lowering means comprise a feedback loop incorporating means of temperature measurement, a controller and a thin film heater.

18. A biological material substantially cryopreserved by a method substantially as defined in any of claims 1 to 11.

Fig.1.





Fig.2.



2/4

Fig.3.




Fig.4.




Fig.5.




Fig.6.





Fig.7.



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 98/03160

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A01N1/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 23907 A (WOELDERS HENRI ; STICHTING INSTITUUT VOOR DIERH (NL)) 4 June 1998 see page 6, line 15 - page 7, line 19; figures 4,6 --- -/--	1-8, 10-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"G" document member of the same patent family

Date of the actual completion of the international search

2 February 1999

Date of mailing of the international search report

17/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Klaver, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03160

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 104, no. 3, 20 January 1986 Columbus, Ohio, US; abstract no. 17345, A. N. NOVIKOV ET AL.: "Possible application of exponential regimes of cooling during cryopreservation of biological samples." XP002091958 see abstract	1-11,18
X	& A. N. NOVIKOV, S. I. TKACHENKO, T. F. STRIBUL & V. F. RYNDIN: "Possible application of exponential regimes of cooling during cryopreservation of biological samples." BIOFIZIKA, vol. 30, no. 6, 1985, pages 1042-1045, see the whole document	1-11,18
X	WO 91 01635 A (CELL SYSTEMS LTD) 21 February 1991 cited in the application see: page 7, l. 14-16; page 9, l. 11-25; page 28, l. 20-25; page 30, l. 18-28; page 46.	1-8, 10-12, 17,18
X	WO 96 02801 A (SEC DEP FOR FOREIGN AND COMMON ;RANA KRISHEN JUGJIVAN (GB)) 1 February 1996 cited in the application see: page 2, par. 2/3; page 3, par. 3; page 13, par. 3 - page 14, par. 1; Figure 6.	1-8, 10-12,18
X	DE 29 29 278 A (FORSCHUNGSGESELLSCHAFT FUER BI) 29 January 1981 see page 23, paragraph 1-2; figure 1	1-8,10, 11,18
X	US 4 474 015 A (CHRISTMAS MICHAEL J ET AL) 2 October 1984 see: col. 1, l. 65 - col. 2, l. 15; col. 4, l. 66 - col. 5, l. 19; col. 6, l. 9 - 33; figure 1.	12-17
X	DE 31 25 345 A (DITTRICH FRANZ DR ING;WURMTHALER CHRISTOPH DR) 20 January 1983 see: page 12, l. 16 - page 13, l. 11; page 15, l. 11 - page 16, l. 10; page 17, l. 13 - 32.	12-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/GB 98/03160

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9823907 A	04-06-1998	NL 1004619 C AU 5415698 A	27-05-1998 22-06-1998
WO 9101635 A	21-02-1991	AU 6280890 A CA 2064803 A EP 0486598 A WO 9107085 A JP 5502578 T AU 659076 B AU 6757390 A CA 2068993 A EP 0502033 A GB 2255164 A, B JP 5504052 T	11-03-1991 08-02-1991 27-05-1992 30-05-1991 13-05-1993 11-05-1995 13-06-1991 21-05-1991 09-09-1992 28-10-1992 01-07-1993
WO 9602801 A	01-02-1996	AU 2933595 A	16-02-1996
DE 2929278 A	29-01-1981	NONE	
US 4474015 A	02-10-1984	NONE	
DE 3125345 A	20-01-1983	NONE	